| Biotech Co (Country/ Symbol) | Pharma Co (Country/ Symbol) | Type/ Product Area | Amount (M) | Terms/ Details (Month) |
| Access Pharmaceuticals Inc. (OTC BB:AXCS) | Mipharm SpA (Italy) | Various formulations of amlexenox for treating several diseases, including mucositis, oral lichenplanus and atopic dermatitis | ND | Mipharm gains marketing rights for Italy, Switzerland, Turkey and Lebanon; Access has granted Mipharm manufacturing rights for Europe for the products; Mipharm will make an equity investment in Access, and pay up-front licensing fees and milestones; Access also will receive a percentage of product sales in covered territories; Mipharm receives an option to license other Access products in dermatology and gynecology (3/00) |
| Active Biotech AB (Sweden; ACTIB) | Aventis Pasteur (unit of Aventis SA; France; NYSE:AVE) | Collaboration within the field of diarrhea diseases | ND | Aventis will assume marketing, sales and distribution of Active Biotech s cholera vaccine, SBL Cholera Vaccine, for all countries worldwide outside the U.S. and Europe (8/00) |
| Alliance Pharmaceutical Corp. (ALLP) | Baxter Healthcare Corp. (NYSE:BAX) | Alliance's Oxygent (perflubron emulsion) oxygen car rier in the U.S., Canada and Europe | $50 | Baxter will purchase $20M of convertible preferred stock in Alliance and is required to invest an additional $30M in such stock over the next 18 months as clinical trials progress; Alliance will also receive royalties and an ongoing share of profits (5/00) |
| AlphaOne Pharmaceuticals Inc. | Baxter Healthcare Corp. (NYSE:BAX) | Recombinant a-1 antitrypsin to treat hereditary, emphysema and possibly other pulmonary indica tions | ND | Baxter gains exclusive worldwide marketing and distribution rights for rAAT to treat hereditary emphysema, with an option to develop the product for other pulmonary indications (4/00) |
| AltaRex Corp. (Canada; TSE:AXO) | Genesis Pharma SA (member of MSJ Group; Greece) | Altarex s OvaRex and other antibody-based immunotherapeutic cancer products | ND | Genesis gains rights to market the products in Greece, Turkey, Cyprus and the Balkans; AltaRex will supply the antibody for clinical study; Genesis will provide infrastructure for distribution and billing purposes and cover all remaining costs associated with regulatory approval in the region; resulting profits will be distributed equally to all parties (6/00) |
| AltaRex Corp. (Canada; TSE:AXO) | Medison Pharma (Israel) | AltaRex s OvaRex and other antibody-based cancer therapeutics | ND | Companies created a joint venture for commercialization in Israel and the Middle East; AltaRex will supply the antibody for clinical study in Israel both before and after U.S. approval; Medison will provide infrastructure for distribution and billing purposes, and will be responsible for local drug development costs; resulting profits from commercialization will be distributed equally (7/00) |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Natrol Inc. (NTOL) | Salive | ND | Supply agreement gives Natrol marketing and distribution rights to Salive (12/00) |
| Angstrom Pharmaceuticals Inc. | CalbiochemNovabiochem Corp. | Catalogue of reagents based on the urokinase plasmino gene activator and its receptor | ND | Calbiochem will distribute the reagents worldwide (1/00) |
| Athersys Inc. | Covance Biotechnology Services Inc. (unit of Covance Inc.; NYSE:CVD) | Undisclosed therapeutic protein | ND | Covance will manufacture bulk product for preclinical and clinical studies (6/00) |
| Atrix Laboratories Inc. (ATRX) | Genmedix Ltd. (unit of Merck KgaA; Germany) | Atrix's Atrisorb and Atrisorb dental products | ND | Genmedix will distribute Atrix's dental products in Israel and the Palestinian Authority (3/00) |
| Aurora Biosciences Corp. (ABSC) | Greiner Bio-One GmbH (Austria) | Microplates and other plastic consumables | ND | Aurora granted Greiner nonexclusive rights to develop, manufacture, market and distribute its 3,456-well NanoWell Assay Plate for use with its UHTSS platform, as well as other consumables; the companies will collaborate on the development of new products; agreement includes an up-front technology access fee, as well as royalties (11/00) |
| Avanir Pharmaceuticals Inc. (AMEX:AVN) | SmithKline Beecham plc (UK; NYSE:SBH) | Avanir's docosonal 10% cold cream as a treatment for sores | $25 | SmithKline gains rights to market the product for cold sores in the U.S. and Canada, and will also manufacture the product; Avanir receives an up-front licensing payment and milestones of up to $25M, plus royalties on any sales; SmithKline has an option to negotiate for rights in countries not currently covered outside the U.S. and Canada (4/00) |
| Avigen Inc. (AVGN) | Bayer AG (Germany) | Coagulin-B gene therapy for hemophilia B | $60 | Avigen will get a $15M up-front equity investment, in addition to development and manufacturing costs, milestone payments and royalties; marketing deal (11/00) |
| Axiom Biotechnologies Inc. | Biacore International (Sweden; BCOR) | Biacore will distribute Axiom s new high-throughput pharmacology system, HT-PS 100, on a worldwide basis | $4 | Biacore made an equity investment of $4M in Axiom; Biacore has been granted option to increase its stake in the company at a predetermined price; the agreement includes copromotion rights to selected cell lines developed by Axiom and an option for Biacore to license Axiom's multi-channel, highthroughput system HT-PS Ultra (5/00) |
| Bio-Technology General Corp. (BTGC) | Al-Kindi Pharmaceutical Industries (Jordan) | BTG's Bio-Hep-B vaccine, Bio-Tropin, Oxandrin and BioLon | ND | Al-Kindi has exclusive rights to distriibute the BTG products in Jordan and other countries in the Middle East and North Africa; BTG will supply the products and Al-Kinda will register and market them in the licensed territory (3/00) |
| Bio-Technology General Corp. (BTGC) | Teva Pharmaceutical Industries Ltd. (Israel; TEVA) | BTG's recombinant human growth hormone | ND | Teva will market the product exclusively in the U.S. under 9/99 agreement; announcement marks disclosure of first product covered under the $20M agreement (3/00) |
| Bio-Technology General Corp. (BTGC) | Abbott Laboratories (NYSE:ABT) | Bio-Technology's Oxandrin, an oral anabolic agent to promote weight gain | ND | Abbott will co-market Oxandrin (FDAapproved) in the U.S. (5/00) |
| Boston Life Sciences Inc. (BLSI) | MDS Nordion Inc. (Canada; unit of MDS Inc.; NYSE:MDZ; TSE:MDS) | Altropane | ND | MDS will supply Altropane for BLSI s regulatory filing seeking marketing approval for the Parkinson s diagnostic agent; the agreement calls for MDS to also manufacture Altropane for the commercial market if and when it is approved (8/00) |
| Carrington Laboratories Inc. (CARN) | Medline Industries Inc. | Carrington s wound and skin care products | $60 | Carrington granted Medline exclusive rights to sell and market the products; the deal is worth $50M to $60M over a five-year term, including a $12.5M consideration for royalties (11/00) |
| Celgene Corp. (CELG) | Novartis Pharma AG (Switzerland; NYSE:NVS) | D-methylphenidate, Celgene's chirally pure version of Ritalin | ND | Novartis gains exclusive worldwide rights, excluding Canada; Celgene will receive substantial up-front fees and milestones, plus royalties; Celgene has also granted rights to all its related intellectual properties and patents; Celgene retains marketing rights to the new form and formulations of Ritalin for use in the oncology market; Novartis will fund all remaining development and marketing expenses (4/00) |
| Cell Pathways Inc. (CLPA) | Innovex; Livingston Healthcare Services Inc.; and Lash Group Inc. | Aptosyn (exisulind; orally active drug designed to induce apoptosis in precancerous cells; inhibits a cyclic GMP phosphodiesterase); under consideration at FDA for familial adenomatosus polyposis | ND | Cell Pathways signed three agreements for U.S. sales and distribution of Aptosyn; Innovex will hire and train a dedicated sales force for Cell Pathways to launch and promote Aptosyn in the U.S.; Livingston will be responsible for customer service and other administrative tasks; Lash Group will develop and implement support services for Aptosyn (1/00) |
| Cell Pathways Inc. (CLPA) | Aventis Pharmaceuticals Inc. (unit of Aventis SA, France; NYSE:AVE) | Aventis Nilandron for treatment of advanced prostate cancer | ND | Cell Pathways gained rights to market Nilandron to urologists in the U.S. and Puerto Rico; Cell Pathways will receive a percentage of sales (7/00) |
| Cell Pathways Inc. (CLPA) | Paladin Labs (Canada; TSE:PLB) | Aptosyn (exisulind) for treatment of precancerous colon polyps in patients with familial adenomatous polyposis | ND | Paladin gains exclusive rights in Canada (7/00) |
| Cellomics Inc. | Beckman Coulter Inc. (NYSE:BEC) | Cellomics High Content Screening Technologies for drug discovery | ND | Companies will co-market Cellomics' ArrayScan II instrument and application software, HitKit Reagents and certain informatics products in North America and selected European countries; Beckman Coulter will exclusively distribute ArrayScan II and ArrayScan Kinetics Reader instruments, Cellomics Store and Cellomics Screen informatics products and will serve as sales agent for HitKit; companies will also create Cell Technology Centers of Excellence within academic and non-profit institutions and collaborate in mutual fields of interest (6/00) |
| Cel-Sci Corp. (AMEX:CVM) | Bio Science Contract Production Corp. | Multikine, a natural mixture of human cytokines now in Phase II trials for head and neck cancer | ND | Companies signed a long-term agreement under which Cel-Sci's trained staff will make the product at BSC's Baltimore facility (6/00) |
| Cel-Sci Corp. (AMEX:CVM) | Orient Europharma (Taiwan) | Multikine | ND | Orient gains certain exclusive marketing rights for Multikine in Taiwan, Singapore, Hong Kong and Malaysia; it will fund clinical testing in those countries; Cel-Sci will manufacture the product; the two companies will share in revenues (11/00) |
| Cephalon Inc. (CEPH) | Laboratoire L. Lafon (France) | Cephalon's Provigil for treatment of excessive daytime sleepiness associated with narcolepsy | ND | Cephalon gained rights to market Provigil throughout Latin America and several countries in Asia, in addition to rights it already has in various territories, including the U.S., where the drug is approved (3/00) |
| Cephalon Inc. (CEPH) | Medtronic Inc. (NYSE:MDT) | Medtronic s Intrathecal Baclofen (ITB) Therapy for treatment of severe spasticity | ND | Cephalon is responsible for promoting ITB to neurologists under co-promotion agreement; Medtronic will provide training and support related to the device for ITB Therapy; agreement is for an initial one-year term, and will renew automatically unless terminated by either party (4/00) |
| Cephalon Inc. (CEPH) | Abbott Laboratories Inc. (NYSE:ABT) | Gabitril | $100 | Abbott will transfer U.S. product rights to Gabitril to Cephalon, giving the company the right to market, sell and further develop the drug; Cephalon will pay Abbott $100M over the next four years and will make an additional payment based on the product s patent life (11/00) |
| Cephalon Inc. (CEPH) | Choongwae Pharma Corp. (Korea) | Provigil (modafinil) | ND | Cephalon granted Choongwae rights to market, sell and distribute Provigil in the Republic of Korea (11/00) |
| Cephalon Inc. (CEPH) | Novartis Pharma AG (Switzerland) | Provigil (modafinil) | $40 | Companies will consolidate the sales and marketing efforts of four Novartis central nervous system compounds with Cephalon s Provigil for narcolepsy in the UK; Cephalon will pay Novartis about $40M and the companies will share revenues generated (11/00) |
| Cepheid Inc. (CPHD) | Biomedical Group (unit of Takara Shuzo Co. Ltd.; Japan) | Cepheid Smart Cycler system | ND | The Biomedical Group received an exclusive multi-year right to distribute and market the Smart Cycler system to life sciences markets in Japan, Taiwan and South Korea (7/00) |
| Cepheid Inc. (CPHD) | Eurogentec SA (Belgium) | Cepheid Smart Cycler system | ND | Eurogentec will provide sales, marketing and technical support for the Smart Cycler and will serve as the exclusive distributor in Belgium, France, Germany, the Netherlands, Switzerland and the UK (12/00) |
| ChemBlock International (Russia) | ChemDiv Inc. | Compound libraries | ND | ChemDiv gains exclusive worldwide distribution rights to ChemBlock s collection for use with its Lead Generation and Rapid Analog Delivery programs (2/00) |
| Chiron Corp. (CHIR) | Aventis Pasteur (unit of Aventis SA; France; NYSE:AVE) | Menjugate (menigococcal C vaccine) and Fluad (adjuvenated influenza vaccine) | ND | Aventis will co-promote Menjugate in the UK and Ireland and distribute the product under its own label in the rest of Europe; Aventis will co-promote Fluad in Europe (7/00) |
| CollaGenex Pharmaceuticals Inc. (CGPI) | Willvonsder & Marchesani Ges.m.b.H.& Co. KG (Austria) and Karr Dental Ltd. (Switzerland) | CollGenex s Periostat for periodontal disease | ND | W&M and Karr obtained rights to market Periostat in Austria and Switzerland; both will pay fees associated with the regulatory approvals of Periostat and purchase the drug from CollaGenex via its UK subsidiary, CollaGenex International Ltd. (6/00) |
| CollaGenex Pharmaceuticals Inc. (CGPI) | Showa Yakuhin Kako Co. Ltd. (Japan) | Showa gains rights to market and supply CollaGenex s Periostat exclu sively in Japan, with an option to extend its rights to other Southeast Asian countries | ND | Showa will pay milestone fees associated with the development and regulatory approvals of Periostat in Japan, will coordinate the clinical and regulatory development of Periostat required for marketing authorization by Japan, and either purchase Periostat or develop its own Japanese manufacturing capability, in which case Showa will pay a royalty on net sales to CollaGenex (8/00) |
| CollaGenex Pharmaceuticals Inc. (CGPI) | Taro International Ltd. (unit of Taro Pharmaceutical Industries Ltd.; Israel; TARO) | Taro gains rights to market and supply CollaGenex s Periostat in Israel s dental care market | ND | Taro will pay milestone fees associated with regulatory approvals of Periostat and will be purchasing Periostat from CollaGenex via its wholly owned UK subsidiary, CollaGenex International Ltd.; financial terms were ND (8/00) |
| Commonwealth Biotechnologies Inc. (CBTE) | CosmoBio Co. Ltd. and KN International LLC (both of Japan) | Commonwealth s AccuTrac DNA sequencing aid | ND | CosmoBio and KN gain nonexclusive licenses to market the product (2/00) |
| Connetics Corp. (CNCT) | F.H. Faulding & Co. Ltd. (Australia) | Connetics' ConXn (recomginant human relaxin), under development as a therapy for scleroderma and peripheral vascular disease | $0.50 | Connetics will receive $0.5M in cash, milestones for new indications and royalties on any sales; Faulding gains rights to develop and commercialize the product in Australia (4/00) |
| Cyanotech Corp. (CYAN) | Kyowa Engineering Co. (Japan) | BioAstin | ND | Cyanotech signed an agreement with Kyowa for the distribution of BioAstin in Japan; the three-year agreement calls for an upfront payment to Cyanotech and an additional payment prior to the initiation of two clinical trials (11/00) |
| Cytogen Corp. (CYTO) | Draximage (unit of Draxis Health Inc.; Canada; TSE:DAX; DRAX) | BrachySeed implant, used in treatment of localized cancers, primarily prostate cancer | ND | Draximage will market and distribute Cytogen s BrachySeed implant, receiving both milestone payments and royalties on sales (9/00) |
| Cytogen Corp. (CYTO) | Draxis Health Inc. (Canada) | BrachySeed implants | ND | Cytogen will market and distribute BrachySeed implants for prostate cancer in the U.S. and Draxis will supply radioactive seed to Cytogen for sale in the U.S. under the 10year license, distribution and supply agreement (12/00) |
| GeneData AG (Switzerland) | Teijin Systems Technology Ltd. (Japan) | GeneData's software systems for genome analysis and genome data management | ND | Teijin will represent GeneData and its products in the Japanese market (3/00) |
| Genelabs Technologies Inc. (GNLB) | Watson Pharmaceuticals Inc. | Aslera | $55 | Watson was granted an exclusive license for North American rights to Aslera; the companies also are joining forces on the development of indications for Aslera aside from systemic lupus erythematosus; Watson will pay milestone payments and fees up to $55M, as well as royalties; Watson agreed to purchase 3M shares of Genelabs for $20.5M (11/00) |
| Generex Biotechnology Corp. (GNBT) | Solvay Fluorides Inc. | Solkane 134a pharma | ND | Generex will purchase its requirements for this propellant from Solvay, which will supply it exclusively to Generex for use with pharmaceutical products delivered to the buccal cavity (10/00) |
| Genomic Solutions Inc. | PerkinElmer Inc. (NYSE:PKI) | Biochips and proteomic systems | ND | PerkinElmer will have exclusive distribution rights worldwide with the exception of the U.S., UK and Japan; in those countries PerkinElmer and Genomic Solutions will sell co-branded products; companies also will collaborate to leverage intellectual property and technologies; PerkinElmer receives an equity stake in Genomic Solutions, with an option to acquire control (1/00) |
| Genta Inc. (GNTA) | Avecia Ltd. | Genasense | ND | The two-year agreement is for the supply of Genasense for its continued development (12/00) |
| Genzyme General (GENZ) | Biobras SA (Brazil) | Thyrogen (hormone for follow-up screening of patients treated for thyroid cancer) | ND | Biobras will exclusively distribute and market Thyrogen in Brazil; Genzyme will receive a series of payments (2/00) |
| Hemispherx Biopharma Inc. (AMEX:HEB) | Biovail Corp. International (Canada) | Ampligen, for treatment of chronic fatigue immune deficiency syndrome (CFIDS), also known as myalgic encephalomyelitis | $2 | Biovail gains exclusive rights to market Ampligen in Canada in return for purchasing $2M in Hemispherx common shares (2/00) |
| Hemosol Inc. (Canada; TSE:HML) | Dompe Farmaceutici SpA (Italy) | Hemolink | C$5 (US$3.3) | Hemosol entered into a memorandum of understanding for the marketing of Hemolink in Southern and Eastern Europe; Dompe will make a C$5M investment in Hemosol common shares at C$15 per share, and it has a 16-month option to make a further equity investment of C$5M at C$22.50 per share (10/00) |
| ICN Pharmaceuticals Inc. (NYSE:ICN) | Eli Lilly and Co. (NYSE:LLY) | Cesamet (nabilone) for management of severe nausea and vomiting associated with cancer chemotherapy | ND | ICN will market and distribute Cesamet in Canada (6/00) |
| Incyte Genomics Inc. (INCY) | Multiple companies from around the world | Incyte s clone reagent sets or copies of genes and gene-based research and services, including LifeSeq Gene-by-Gene | ND | Incyte signed 19 distribution agreements allowing various companies to market, sell and distribute Incyte s clone reagent sets and gene-based research tools and services; financial terms were ND (8/00) |
| Kreatech Biotechnology BV (the Netherlands) | NEN Life Science Products | ULS, a chemical labeling technique, for use with microarrays | ND | NEN is the exclusive worldwide marketing partner, with rights to develop and sell products for both the research and diagnostic markets (2/00) |
| LifeCell Corp. (LIFC) | Obagi Medical Products | Cymetra, which consists of small particles of processed acellular human tissue matrix, for non-surgical softtissue replacement | $1 | Obagi gains rights to co-promote product to office-based dermatologists and plastic surgeons in exchange for a $1M up-front fee; Obagi will receive a co-promotion fee based on a percentage of net sales; the companies jointly will oversee the development and implementation of marketing programs (2/00 |
| Medarex Inc. (MEDX) | Scil Biomedicals GmbH (Germany) | Mederax s MDX-RA for prevention of secondary cataracts, and MDX-210 for the treatment of HER2 overexpressing tumors | $29 | Scil licensed development and marketing rights in Europe and the Near East for $4M up front plus royalties on sales; Scill also committed up to $25M to support further development in its territories and in North America, but is entitled to receive milestones from Medarex; Scil will pay 100% of remaining development costs for MDX-RA; for MDX-210, Scil received commercial rights other than for cellular therapy; Medarex can opt to pay a portion of development costs for MDX-210 and retain all commercial rights in its territory, or it can elect for Scil to pay all costs up to $17M and give Scil co-marketing rights in the U.S.; excess costs would be shared equally (1/00) |
| Mylan Pharmaceuticals (unit of Mylan Laboratories; NYSE:MYL) | Genpharm Inc. | Two undisclosed Genpharm products | ND | Mylan will market two Genpharm products, with Genpharm as the holder of the U.S. registration and Mylan as the exclusive marketer in the U.S; manufacturing will be coordinated through Genpharm (8/00) |
| Myriad Genetics Inc. (MYGN) | Falco Biosystems Ltd. (Japan) | Myriad s BRACAnalysis test for breast and ovarian cancer risk and its CardiaRisk test for hypertension and cardiovascular disease | $3 | Falco paid $3M up front, and will pay royalties on sales; additional products may be added, at Falco s option; Falco will hold exclusive license in Japan for six years, provided performance milestones are met; agreement is renewable after initial six-year term (2/00) |
| Myriad Genetics Inc. (MYGN) | Rosgen Ltd. (UK) | Myriad s BRACAnalysis genetic test for breast and ovarian cancer risk | ND | Five-year, renewable agreement includes up-front fee, milestones and royalties on sales in the UK and Ireland (3/00) |
| Myriad Genetics Inc. (MYGN) | MDS Inc. (Canada; NYSE:MDZ; TSE:MDS) | Colaris | ND | Myriad expanded its exclusive marketing collaboration with MDS, allowing MDS to market Colaris colon cancer predictive medicine product in Canada; MDS is Myriad s exclusive marketing partner for hereditary breast and ovarian cancer predictive testing in Canada (10/00) |
| Nabi (NABI) | Collaborative BioAlliance Inc. (affiliate of The Collaborative Group Ltd.) | StaphVAX (Staphylococcus aureus type 5 and type 8 capsular polysaccharide conjugate vaccine) | ND | Collaborative BioAlliance will manufacture the vaccine at its cGMP manufacturing facility in Smithfield, R.I. (5/00) |
| NeoRx Corp. (NERX) | International Isotopes (INIS) | NeoRx s Skeletal Targeted Radiotherapy product for treatment of multiple myeloma | $1.30 | International Isotopes will manufacture the product for Phase III clinical trials; NeoRx will provide $1.3M for pilot plant development; International Isotopes will be responsible for all aspects of manufacturing, including process qualification, quality control, packaging and shipping (2/00) |
| Nexell Therapeutics Inc. (NEXL) | Takara Shuzo Co. Ltd. (Japan) | Nexell's cell therapy platform, with initial focus on producing a commercial gene therapy platform by combining the Nexell Lifecell X-Fold cell culture container with Takara RetroNectin (recombinant human fibronectin fragments) | ND | Takar will exclusively distribute Nexell cell therapy products in Japan, Korea, Taiwan and China; Nexell receives a multimillion-dollar up-front payment (5/00) |
| Nymox Pharmaceutical Corp. (NYMX) | Pharmatech Business Services Inc. | Distribution and marketing agreement for the 7C Gold NTP test for use in Alzheimer s disease | ND | Nymox will provide the new test as an aid to physicians, and Pharmatech will provide its product distribution, billing, reimbursement and collection services in the U.S. (9/00) |
| Orphan Medical Inc. (ORPH) | IDIS World Medicines (UK) | Orphan's Antizol (fomepizole) injection for ethylene glycol poisoning, Bulsulfex (bulsulfen) injection for use in bone marrow and stem cell transplantation, plus three other products | ND | IDIS will distribute all of Orphan's products in countries where Orphan is not currently represented (3/00) |
| Orphan Medical Inc. (ORPH) | Medizinisch Handelsgesellschaft (Germany) | Busulfex (busulfen) in jection for use in bone marrow and stem cell transplantation | ND | MHG will provide Busulfex to physicians requesting the product in Germany (3/00) |
| Orphan Medical Inc. (ORPH) | Kirin Brewery Co. Ltd. (Japan) | Busulfex (busulfen) | ND | Kirin gained exclusive rights to market and distribute Busulfex injection in Asia, including Japan, China, South Korea and Taiwan (12/00) |
| PathoGenesis Corp. (PGNS) | Dompe (Italy) | TOBI (tobramycin solution for inhalation) for treating infections in patients with cystic fibrosis | ND | Dompe will promote and distribute TOBI in Italy (2/00) |
| PowderJect Pharmaceuticals plc (UK; LSE:PJP) | The BOC Group (UK; LSE:BOC) | Helium micro-cylinder that acts as the PowderJect drug delivery device s internal power source | ND | PowderJect worked with BOC on development and pilot manufacturing of the device; under new agreement, BOC will be responsible for construction, management and funding of commercial-scale micro-cylinder production facility, expected to start production in 2002 (1/00) |
| Procyon Biopharma Inc. (Canada) | Biovail Corp. (Canada) | Fibrostat, a topical cream for treatment of scars resulting from surgery or burns | C$1.5 (US$1) | Agreement commits Biovail to a financing of C$1.5M (US$1M) for completion of development in Canada; upon approval, Procyon will receive an additional C$1M (US$0.7M) milestone, as well as a doubledigit percentage royalty on sales; Fibrostat will be developed in collaboration with, and will by marketed by, Crystaal, Biovail s Canadian marketing division (2/00) |
| Protein Polymer Technologies Inc. (PPTI) | Femcare Ltd. (UK) | Urethral bulking agent for female stress incontinence based on a bio material created by combining features of natural silk and human human elastin into a recombinant protein formulation | $1 | Femcare will market product in Europe and Australia; Protein Polymer will provide technical assistance and product supplies for Femcare s clinical and regulatory activities for approvals in Europe and Australia; Femcare will pay a $1M licensing fee and royalties on sales; Protein Polymer will provide product supplies for sales (1/00) |
| Questcor Pharmaceuticals Inc. (AMEX:QSC) | Ahn-Gook Pharmaceuticals Inc. (South Korea) | Emitasol | ND | Ahn-Gook will market Emitasol in Korea; Questcor will receive an up-front cash and a milestone payment and royalties on sales (12/00) |
| Ribozyme Pharmaceuticals Inc. (RZYM) | Avecia LifeScience Molecules (UK) | Ribozyme manufacturing processes and intellectual property | ND | RPI will transfer manufacturing processes and significant intellectual property to Avecia, whose Advanced Medicines manufacturing facilities at Grangemouth, Scotland, will enable both clinical trials and cost-effective commercial manufacture of ribozymes (2/00) |
| Salix Pharmaceuticals Group plc (Canada; TSE:SLX) | Shire Pharmaceuticals Group plc (UK; SHPGY) | Balsalazide, a treatment for ulcerative colitis | $24 | Shire will pay up to a total of $24M for exclusive rights in Austria, Belgium, Denmark, Finland, France, Germany, Iceland, Ireland, Luxembourg, Norway, the Netherlands, Switzerland, Sweden and the UK; fees include $12.1M up front ($9.6M in cash and $2.5M in equity purchase) (5/00) |
| SkyePharma plc (UK; SKYE) | Bioglan Pharma plc (UK) | Solarase, a topical gel for actinic keratosis that is approved in five member states of the European Union | ND | Bioglan will pay a licensing fee and royalties on sales (3/00) |
| SkyePharma plc (UK; SKYE) | Paladin Labs Inc. (Canada; VSE:PLB) | SkyePharma s DepoCyt (injectable sustainedrelease cytarabine) | $1 | Paladin Labs gains exclusive Canadian marketing and distribution rights for DepoCyt; SkyePharma will receive an up-front payment of $1M, additional milestone payments tied to future events and a significant share of future revenues (7/00) |
| Synsorb Biotech Inc. (SYBB) | Tramedico International BV (the Netherlands) | Synsorb Pk, designed to prevent serious complications associated with verotoxigenic E. coli infections | ND | Tramedico will market and distribute the product in the Netherlands, Belgium and Luxembourg; Synsorb will supply the product and receive an up-front payment, milestones and a share of sales revenue; Tramedico will be responsible for all costs associated with distribution, marketing and sales (2/00) |
| United Therapeutics Corp. (UTHR) | Paladin Labs Inc. (Canada; TSE:PLB) | Uniprost, a synthetic variation of the prostacyclin molecule, for treatment of pulmonary hypertension | ND | Paladin gains exclusive Canadian distribution rights (2/00) |
| United Therapeutics Corp. (UTHR) | AOP Orphan Pharmaceuticals AG (Austria) | Uniprost, a subcutaneous prostacyclin therapy in Phase III trials for treatment of late-stage pulmonary hypertension | ND | AOP will distribute Uniprost in Austria, Switzerland, the Czech Republic, Poland, Hungary, Slovakia and Slovenia (3/00) |
| United Therapeutics Corp. (UTHR) | Antigen Pharmaceuticals Ltd. (Ireland) | UT-15 (Uniprost) | ND | Antigen will distribute UT-15 (Uniprost) in the UK and Ireland (11/00) |
| United Therapeutics Corp. (UTHR) | Professional Detailing Inc. | Beraprost | ND | Professional Detailing will provide prelaunch and commercialization services for beraprost in the U.S. (11/00) |
| Virco | Gilead Sciences Inc. (GILD) | Virco s HIV resistance monitoring tests and services | ND | Gilead will promote the Virco portfolio of tests and services to HIV-treating physicians in the U.S.; companies expect to extend collaboration to Europe and Australia (3/00) |
| Vivus Inc. (VVUS) | Abbott Laboratories (NYSE:ABT) | Vivus transurethral products Muse (alprostadil) and Alibra for the treatment of erectile dysfunction | ND | Abbott gains exclusive rights for Muse and Alibra in selected markets, including Europe, Japan, Australia, New Zealand and South and Central America; Abbott has the option to co-develop and license future Vivus transurethral products in this territory (6/00) |
| XOMA Ltd. (XOMA) | Baxter Healthcare Corp. (unit of Baxter International; NYSE:BAX) | Neuprex, XOMA s Phase III recombinant bactericidal/permeability-increasing protein for treatment of meningo coccemia and all future antibacterial and antiendotoxin indications | $35 | Baxter will make up-front and other payments related to the meningococcemia indication totaling $35M; additional payments will be made upon the achievement of development milestones for future indications; Baxter will pay all future clinical development costs, as well as royalties; under separate supply agreement, a XOMA affiliate will manufacture the product; Baxter has future manufacturing rights (1/00) |
| Notes: This chart does not cover agreements between biotech companies or agricultural agreements. It covers the time between 1/1/00 and 12/31/00; stocks trade on NASDAQ unless otherwise noted. AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchang; VSE = Vancouver Stock Exchange. ND = Not disclosed, reported and/or available ** Denotes the date the item ran in BioWorld International. | ||||
